At this year's European Society of Medical Oncology (ESMO) Congress — held virtually from September 18–21 in Madrid, Spain — investigators reported the latest findings in cancer research. Here, NEJM Journal Watch Oncology and Hematology Editor-in-Chief William J. Gradishar reviews key presentations of new breast cancer treatments.
Sacituzumab Govitecan for Previously Treated Patients with Triple-Negative Breast Cancer
Bardia and colleagues reported results of the randomized, phase III ASCENT trial (abstract LBA17), which compared the antibody drug conjugate sacituzumab govitecan (SG) with physicians' treatment of choice (PTC; eribulin, vinorelbine, gemcitabine, or capecitabine) in 529 previously treated patients with triple-negative breast ca…
Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)